Application of a reagent for downregulating RBM7 expression in the preparation of a drug for treating liver cancer

By combining reagents that downregulate RBM7 expression with the anti-aging drug senolytics, the lack of RBM7-targeted drugs in liver cancer treatment has been addressed. This approach significantly inhibits liver cancer cell proliferation and improves patient survival, providing biomarkers for liver cancer diagnosis and prediction.

CN118078998BActive Publication Date: 2024-11-12THE SECOND HOSPITAL OF DALIAN MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410192278.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-02-21
Publication Date
2024-11-12
Estimated Expiration
2044-02-21

AI Technical Summary

Technical Problem

Current technologies lack effective treatments targeting RBM7 to combat the progression of liver cancer, and existing molecularly targeted drugs such as sorafenib develop resistance after several months of treatment. There is also a lack of clinical drugs that can induce senescence in liver cancer cells.

Method used

By using reagents that downregulate RBM7 expression, including RBM7 knockdown vectors and the small molecule inhibitor abemaciclib, combined with the anti-aging drug senolytics, senescence of liver cancer cells is induced and proliferation of liver cancer cells is inhibited. Furthermore, by targeting RBM7 to regulate p21 mRNA stability, the killing effect of the anti-aging drug on liver cancer cells is enhanced.

Benefits of technology

It significantly inhibits the proliferation of liver cancer cells, enhances the killing effect of anti-aging drugs on liver cancer cells, provides new ideas for liver cancer treatment, improves patient survival, and provides biomarkers for liver cancer diagnosis and prediction.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118078998B_ABST
    Figure CN118078998B_ABST
Patent Text Reader

Abstract

The present invention belongs to the technical field of biological medicines, and provides an application of a reagent for down-regulating RBM7 expression in preparing a drug for treating liver cancer. The reagent for down-regulating RBM7 expression comprises a vector for knocking down RBM7 and a small molecule compound abemaciclib; the backbone vector of the vector for down-regulating RBM7 expression is a pLK0.1 vector; primers for constructing the vector for down-regulating RBM7 expression comprise an RBM7 sh1 primer pair and an RBM7 sh2 primer pair; the present invention discloses a new function and mechanism of RBM7 in participating in the aging of liver cancer cells by regulating the stability of p21 mRNA, and also provides a new idea and scheme for the treatment of liver cancer by targeting RBM7 and combining it with anti-aging drugs senolytics, thus opening up a new clinical application prospect for the treatment strategy of aging-related tumors, and at the same time indicates that the expression level and gene status of RBM7 can be used as biomarkers for designing anti-liver cancer treatment schemes for pro-aging therapies.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biological medicines, and in particular to an application of a reagent for downregulating RBM7 expression in the preparation of a medicine for treating liver cancer. Background Art

[0002] Liver cancer is the third most common cause of cancer death worldwide, and its incidence is increasing rapidly every year. Most patients with liver cancer are diagnosed at an advanced stage and are therefore not suitable for surgical resection, and there is a lack of effective treatments. The limitations of the application of molecular targeted drugs are one of the reasons for the poor prognosis of liver cancer. Although sorafenib, as a first-line anti-angiogenic drug, is currently one of the effective treatments for advanced liver cancer, patients show resistance to sorafenib after several months of treatment. Therefore, exploring new therapeutic targets is crucial to combat liver cancer progression and improve patient prognosis.

[0003] There is increasing evidence that interventions that induce senescence (such as chemotherapy, radiation or immunotherapy or epigenetic regulators) have significant anti-tumor effects in a variety of cancer types. However, the therapeutic effects of pro-aging therapy and its specific drug regimens on liver cancer are not clear. Cellular senescence is the initial barrier to prevent the malignant transformation of tumors, because cell senescence can force tumor cells into growth arrest on the one hand, and the senescence-associated secretory phenotype (SASP) can trigger an immune clearance effect, which helps to eliminate harmful cells that promote tumor progression. If senescent cells escape immune surveillance, it is very likely to promote the malignant transformation of tumors. Therefore, it is urgent to explore the combination of pro-aging therapy and anti-aging drugs (compounds that induce senescent cell death, senolytics) to treat tumors, but there is still a lack of clinical drugs that effectively induce tumor cell senescence.

[0004] RNA binding proteins (RBPs) play a key role in multiple steps of RNA metabolism, including transcription, alternative splicing, RNA stability and translation. Abnormal expression of RBPs is closely related to cell senescence and tumorigenesis. In-depth exploration of the physiological functions of RNA binding proteins and the RNA networks they regulate will help provide new potential targets and therapeutic strategies for future tumor treatment. However, there is still a lack of pro-aging therapy solutions and anti-liver cancer molecular targets designed and developed for RBPs.

[0005] To this end, those skilled in the art have proposed the use of an agent for downregulating RBM7 expression in the preparation of a drug for treating liver cancer to solve the problems raised by the background technology. Summary of the invention

[0006] In order to solve the above technical problems, the present invention provides an application of a reagent for downregulating RBM7 expression in the preparation of a drug for treating liver cancer, so as to solve the problems existing in the prior art.

[0007] A reagent for down-regulating RBM7 expression is used in the preparation of a drug for treating liver cancer, wherein the reagent for down-regulating RBM7 expression preferably comprises a vector for down-regulating RBM7 expression and a small molecule inhibitor abemaciclib. The backbone vector of the vector for down-regulating RBMS1 expression is a pLK0.1 vector; the primers used to construct the vector for down-regulating RBM7 expression include an RBM7 shN1 primer pair and / or an RBM7 shN2 primer pair; the RBM7 shN1 primer pair includes RBM7shN1-F with a nucleotide sequence as shown in SEQ ID NO.1 and RBM7 shN1-R with a nucleotide sequence as shown in SEQ ID NO.2; the RBM7 shN2 primer pair includes RBM7 shN2-F with a nucleotide sequence as shown in SEQ ID NO.3 and RBM7 sh2-R with a nucleotide sequence as shown in SEQ ID NO.4.

[0008] A reagent for downregulating RBM7 is used in the preparation of a drug for inducing cell senescence, wherein the reagent for downregulating RBM7 expression comprises a vector for downregulating RBM7 expression and a small molecule inhibitor abemaciclib. The backbone vector of the vector for downregulating RBMS1 expression is a pLK0.1 vector; the primers used to construct the vector for downregulating RBM7 expression include an RBM7 shN1 primer pair and / or an RBM7shN2 primer pair; the RBM7 shN1 primer pair includes RBM7 shN1-F with a nucleotide sequence as shown in SEQ ID NO.1 and RBM7 shN1-R with a nucleotide sequence as shown in SEQ ID NO.2; the RBM7 shN2 primer pair includes RBM7 shN2-F with a nucleotide sequence as shown in SEQ ID NO.3 and RBM7 sh2-R with a nucleotide sequence as shown in SEQ ID NO.4.

[0009] The invention discloses an application of a reagent for down-regulating RBM7 in the preparation of a drug for inhibiting the proliferation of liver cancer cells. The reagent for down-regulating RBM7 expression comprises a vector for down-regulating RBM7 expression and a small molecule inhibitor abemaciclib. The backbone vector of the vector for down-regulating RBMS1 expression is a pLK0.1 vector; the primers used to construct the vector for down-regulating RBM7 expression include an RBM7 shN1 primer pair and / or an RBM7 shN2 primer pair.

[0010] The invention discloses an application of a reagent for down-regulating RBM7 in the preparation of a drug for regulating p21 expression, wherein the reagent for down-regulating RBM7 expression comprises a vector for down-regulating RBM7 expression and a small molecule inhibitor abemaciclib. The backbone vector of the vector for down-regulating RBMS1 expression is a pLK0.1 vector; the primers used to construct the vector for down-regulating RBM7 expression comprise an RBM7 shN1 primer pair and / or an RBM7 shN2 primer pair.

[0011] The invention discloses an application of a reagent for down-regulating RBM7 in the preparation of a drug for enhancing the killing of liver cancer cells by anti-aging cell drugs senolytics, wherein the reagent for down-regulating RBM7 expression comprises a vector for down-regulating RBM7 expression and a small molecule inhibitor abemaciclib. The backbone vector of the vector for down-regulating RBMS1 expression is a pLK0.1 vector; the primers used to construct the vector for down-regulating RBM7 expression include an RBM7 shN1 primer pair and / or an RBM7 shN2 primer pair. Senolytic drugs include ABT-263 and AZD8035.

[0012] The use of a kit for diagnosing liver cancer and predicting the prognosis of liver cancer patients is prepared according to the expression level of RBM7, wherein the reagent preferably includes an antibody.

[0013] Compared with the prior art, the present invention has the following beneficial effects:

[0014] The present invention reveals the new function and mechanism of RBM7 in participating in the aging of liver cancer cells by regulating the stability of p21 mRNA, and also provides new ideas and solutions for the treatment of liver cancer by targeting RBM7 and combining it with anti-aging drugs senolytics, opening up new clinical application prospects for aging-related tumor treatment strategies. At the same time, it indicates that the expression level and gene status of RBM7 can be used as biomarkers for designing anti-liver cancer treatment plans for pro-aging therapies. BRIEF DESCRIPTION OF THE DRAWINGS

[0015] Figure 1 The present invention provides a graph showing the expression of RBM7 in liver cancer patient tissues; wherein A is a statistical graph showing the expression of RBM7 in human liver cancer tissues and adjacent normal tissues from the TCGA database and the CPTAC protein database using bioinformatics analysis; B is a graph showing the protein expression of RBM7 in fresh frozen cancer tissues (T) and normal tissues (N) of liver cancer patients during surgery detected by immunoblotting technology; C is a graph showing the RNA expression level of RBM7 in fresh frozen cancer tissues (T) and normal tissues (N) of liver cancer patients during surgery detected by real-time fluorescence quantitative PCR technology; and D is a graph showing the correlation between the expression level of RBM7 and the overall survival of liver cancer patients;

[0016] Figure 2The results of the present invention are provided for inhibiting the in vitro proliferation ability of liver cancer cell lines by knocking down RBM7 using pLK0.1-RBM7-sh1 / 2; wherein A is a statistical graph of the protein knockdown efficiency of RBM7 detected in different liver cancer cell lines using an immunoblotting experiment; B is a statistical graph of the effect of knocking down RBM7 on the proliferation ability of HepG2 liver cancer cell lines detected using a CCK8 experiment and a plate cloning experiment; C is a statistical graph of the effect of knocking down RBM7 on the proliferation ability of SNU449 liver cancer cell lines detected using a CCK8 experiment and a plate cloning experiment; D is a statistical graph of the effect of knocking down RBM7 on the proliferation ability of Huh7 liver cancer cell lines detected using a CCK8 experiment and a plate cloning experiment; SNU449 and Huh7 cells were subjected to an in vitro cell proliferation experiment-clone formation and growth curve CCK8 experiment respectively; the P value of the clone formation experiment statistics was calculated using a one-way ANOVA with Dunnett's multiple comparisons test, and the p value of the growth curve graph was calculated using a two-way ANOVA;

[0017] Figure 3 The results of the invention provide a graph showing the effect of knocking down RBM7 using pLK0.1-RBM7-sh1 / 2 on the growth of subcutaneous transplanted tumors in nude mice with hepatocellular carcinoma; wherein A is a photograph of subcutaneous transplanted tumors in nude mice after knocking down RBM7 using pLK0.1-RBM7-sh1 / 2 in Huh7 hepatoma cells or transfecting with an empty vector; B is a statistical graph of the weight of subcutaneous transplanted tumors in nude mice in A; and C is a statistical graph of the curve of the volume of subcutaneous transplanted tumors in nude mice measured at regular intervals;

[0018] Figure 4 The present invention provides an effect of knocking down RBM7 to induce senescence of liver cancer cells; wherein A is a flow cytometry analysis of the effect of knocking down RBM7 on the cell cycle phase distribution of liver cancer cell lines; B is SA-β-Gal staining of liver cancer cell lines with knockdown RBM7 or cells in the control group and the statistical proportion of positively stained cells; C is a real-time fluorescence quantitative PCR analysis of the effect of knocking down RBM7 on the expression of aging-related inflammatory factors in liver cancer cells; D is a co-culture experiment, in which senescent cells with knockdown RBM7 are co-cultured with normal cells expressing GFP green fluorescence for 48 hours, and the morphological changes of GFP cells are observed under a fluorescence microscope; scale = 100 μm; E is a Western Blot experiment to detect the expression of cell cycle inhibitory proteins (CKIs) p21, p-RB, and PAI-1 in liver cancer cell lines with knockdown RBM7 and the control group;

[0019] Figure 5The present invention provides the effect of knocking down p21 to restore RBM7 downregulation on liver cancer cell senescence; wherein A is the protein expression of RBM7 and p21 detected by immunoblotting assay by knocking down RBM7 alone or knocking down RBM7 and p21 simultaneously in HepG2 or SNU449 cells; B is the statistical graph of the control group, the liver cancer cells of the RBM7 knockdown group and the RBM7 and p21 knockdown group being stained with SA-β-Gal, and the positive proportion of senescent cells being calculated; C is the proliferation ability of the liver cancer cells of the control group, the RBM7 knockdown group and the RBM7 and p21 knockdown group detected by CCK8 assay; D is the clone formation ability of the liver cancer cells of the control group, the RBM7 knockdown group and the RBM7 and p21 knockdown group detected by plate cloning assay;

[0020] Figure 6 The present invention provides a result diagram of knocking down RBM7 to regulate the stability of p21 mRNA through the Ago2-RISC complex; wherein A is a real-time fluorescence quantitative PCR experiment to detect the degradation rate of p21 mRNA after treating the control group and the RBM7 knocked down liver cancer cell line HepG2 with 5 μg / ml actinomycin D; B is a 3'-UTR sequence of p21 connected to the pMIR-Reporter plasmid, and the luciferase activity in the transfected cells is detected to identify the effect of RBM7 knockdown on the stability of p21 mRNA, specifically, pMIR-p21-3'UTR Reporter, pMIR-Control Reporter and Renilla plasmids are co-transfected into the control group and the RBM7 knocked down liver cancer cells, respectively, and the ratio of Firefly: Renilla is detected after 48 hours to quantify the activity of luciferase; C is RNA Pull The down experiment detected the binding between different truncations of p21-3'UTR and RBM7 protein; D is the RNA immunoprecipitation experiment to detect the binding between RBM7 protein and the 391-541nt region of p21-3'UTR, in which proRBM39 was used as a positive control; E is the RNAFold website predicting the secondary structure of p21 mRNA, the purple line indicates the binding site of miR-93-5p, and the blue line indicates the binding site of RBM7; F is the RNA pull down to detect the binding between different truncations of p21-3'UTR and Ago2 protein; F is the RNA immunoprecipitation experiment to detect the effect of RBM7 expression on the binding between Ago2 and miR-93-5p;

[0021] Figure 7The results of the RBM7 knockdown sensitization anti-aging drugs (senolytics) provided by the present invention on the killing effect of liver cancer cells; wherein A is the use of senolytics drug ABT-263 and solvent DMSO to treat liver cancer cells in the RBM7 knockdown group and the control group, respectively, and the cell killing rate is detected by CCK8 experiment; B is the use of senolytics drug AZD8055 and solvent DMSO to treat liver cancer cells in the RBM7 knockdown group and the control group, respectively, and the cell killing rate is detected by CCK8 experiment;

[0022] Figure 8 The result graph of the RBM7 small molecule inhibitor abemaciclib induced liver cancer cell senescence provided by the present invention; wherein A is a high-throughput screening of RBM7 small molecule inhibitors using a 3094 compound drug library approved by the FDA, and the specific screening indicators are the fluorescence intensity of the GFP-RBM7 fusion protein, cell viability detection and β-galactosidase staining positive rate; B is an immunoblotting experiment to detect the effect of abemaciclib treatment on the phosphorylation levels of RBM7, p21, and RB in liver cancer cells; C is a plate cloning experiment to detect the effect of abemaciclib treatment on the cloning ability of liver cancer cells; D is a SA-β-gal staining experiment to detect the induction effect of abemaciclib treatment on liver cancer cell senescence;

[0023] Fig. 9 The results of the RBM7 small molecule inhibitor abemaciclib provided by the present invention combined with anti-aging drugs (senolytics) on liver cancer killing effect; wherein A is a CCK8 experiment to detect the killing rate of each group of cells in the treatment of liver cancer cells with abemaciclib alone, AZD8055 alone, and abemaciclib and AZD8055 in combination; B is the effect of abemaciclib alone, AZD8055 alone, and abemaciclib and AZD8055 in combination on the proliferation of liver cancer cells; C is a CCK8 experiment to detect the killing rate of cells in the RBM7 knockdown group and the control group liver cancer cells using the senolytics drug AZD8055 and the solvent DMSO; D is a tumor load nude mouse treatment experiment, in which Huh7 cells were subcutaneously injected into nude mice to form transplanted tumors, and two weeks after oral administration (the schemes were drug solvent group; abemaciclib; AZD8055; abemaciclib and AZD8055 combined), photos and weight statistics of the tumor load in each group of nude mice. DETAILED DESCRIPTION

[0024] The following examples are used to illustrate the present invention but are not intended to limit the scope of the present invention.

[0025] A use of a reagent for downregulating RBM7 expression in the preparation of a drug for treating liver cancer, characterized in that: the reagent for downregulating RBM7 expression comprises a vector for knocking down RBM7 and a small molecule compound abemaciclib;

[0026] The backbone vector of the vector for down-regulating RBMS1 expression is a pLK0.1 vector; the primers used to construct the vector for down-regulating RBM7 expression include an RBM7 sh1 primer pair and an RBM7 sh2 primer pair;

[0027] The RBM7 sh1 primer pair includes RBM7 sh1-F with a nucleotide sequence as shown in SEQ ID NO.1 and RBM7 sh1-R with a nucleotide sequence as shown in SEQ ID NO.2; the RBM7 sh2 primer pair includes RBM7 sh2-F with a nucleotide sequence as shown in SEQ ID NO.3 and RBM7 sh2-R with a nucleotide sequence as shown in SEQ ID NO.4.

[0028] The reagents for down-regulating the expression of RBM7 can be used to prepare drugs for inducing cell senescence, drugs for inhibiting the proliferation of liver cancer cells, drugs for inducing genomic damage of liver cancer cells, and the application of regulating cell cycle regulatory proteins. In addition, the reagents for down-regulating RBM7 can be used to prepare drugs for enhancing the killing of liver cancer cells by anti-aging drugs senolytics, and for the application of kits for liver cancer diagnosis and prediction of the prognosis of liver cancer patients. The experimental results show that the present invention screened the RNA binding protein (RBPs) shRNA lentiviral library and found that the reagents for knocking down RBM7 can not only cause liver cancer cell senescence, but also significantly sensitize the killing effect of senolytic drugs on liver cancer cells. Protein immunoblotting and real-time fluorescence quantitative PCR technology experimental analysis of frozen fresh tissue samples of liver cancer and corresponding adjacent cancers showed that the expression abundance of RBM7 in tumor samples was higher, and the TCGA database bioinformatics analysis showed that liver cancer patients with low expression of RBM7 had a longer overall survival. The pLKO.1-shRNA lentiviral system was used to construct a liver cancer cell line with stable knockout of RBM7. The results of the clone formation experiment, CCK experiment and nude mouse transplant tumor experiment showed that reducing RBM7 significantly reduced the proliferation ability of liver cancer cells in vivo and in vitro. The relevant molecular mechanism research showed that knocking down RBM7 inhibited the AGO2-RISC complex targeting CDKN1A mRNA, thereby inducing liver cancer cell senescence mediated by the accumulation of cell cycle regulatory protein p21. In addition, cytotoxicity experiments proved that knocking down RBM7 enhanced the killing effect of senolytic drugs on liver cancer cells. The small molecule inhibitors of RBM7 were screened using a high-throughput FDA-approved drug library. The experiment showed that the inhibitor abemaciclib that down-regulates RBM7 expression can promote the senescence of liver cancer cells. Abemaciclib combined with the anti-aging drug senolytics can effectively inhibit the progression of liver cancer in a mouse transplant tumor model.

[0029] A reagent for downregulating RBM7 is used in the preparation of a drug for inducing cell senescence. The reagent for downregulating RBM7 expression comprises a vector for downregulating RBM7 expression and a small molecule inhibitor abemaciclib. The backbone vector of the vector for downregulating RBMS1 expression is a pLK0.1 vector; the primers used to construct the vector for downregulating RBM7 expression include an RBM7 shN1 primer pair and / or an RBM7shN2 primer pair; the RBM7 shN1 primer pair includes an RBM7 shN1-F having a nucleotide sequence as shown in SEQ ID NO.1 and an RBM7 shN1-R having a nucleotide sequence as shown in SEQ ID NO.2; the RBM7 shN2 primer pair includes an RBM7 shN2-F having a nucleotide sequence as shown in SEQ ID NO.3 and an RBM7 sh2-R having a nucleotide sequence as shown in SEQ ID NO.4. The present invention constructs a liver cancer cell line with stable knockout of RBM7 by utilizing the pLKO.1-RBM7-shRNA lentiviral system, and the flow cytometry results show that RBM7 knockdown promotes liver cancer cell cycle arrest. Combining the results of microscopic morphological observation, β-galactosidase staining experiment, real-time fluorescence quantitative PCR technology to detect aging-related secretory factors, and immunoblotting experiment to detect the expression of cell cycle regulatory proteins, the present invention confirms that the reagent for knocking down RBM7 can induce a senescence-like phenotype in liver cancer cells

[0030] The invention discloses an application of an agent for downregulating RBM7 in the preparation of a drug for inhibiting the proliferation of liver cancer cells. The agent for downregulating the expression of RBM7 includes a vector for downregulating the expression of RBM7 and a small molecule inhibitor abemaciclib. The backbone vector of the vector for downregulating the expression of RBMS1 is a pLK0.1 vector; the primers for constructing the vector for downregulating the expression of RBM7 include an RBM7 shN1 primer pair and / or an RBM7 shN2 primer pair. The invention uses the constructed liver cancer stable transgenic cell line that stably downregulates RBM7 to perform a cloning experiment and a growth curve experiment. The results show that RBM7 knockdown significantly inhibits the in vitro proliferation ability of liver cancer cells. In addition, 3×106 RBM7 knockdown Huh7 cells or control empty-loaded cells were injected into the armpits of 4-6 week BALB / cnude immunodeficient mice, and a nude mouse transplant tumor experiment was performed. The results showed that knockdown of RBM7 significantly inhibited the tumor-forming ability of liver cancer cells in animals.

[0031] The invention discloses an application of an agent for down-regulating RBM7 in the preparation of a drug for regulating p21 expression, wherein the agent for down-regulating RBM7 expression comprises a vector for down-regulating RBM7 expression and a small molecule inhibitor abemaciclib. The backbone vector of the vector for down-regulating RBMS1 expression is a pLK0.1 vector; the primers used to construct the vector for down-regulating RBM7 expression include an RBM7 shN1 primer pair and / or an RBM7shN2 primer pair. The present invention uses real-time fluorescence quantitative PCR technology and a luciferase reporter gene experiment of a 3' non-coding sequence to conduct a mechanism study and find that RBM7 knockdown significantly increases the mRNA half-life of the p21 transcript (CDKN1A). TargetScan combined with RNA secondary structure prediction analysis, RNA-pull down experiment and RNA immunoprecipitation (RIP) experiment results show that RBM7 regulates p21 mRNA stability by recruiting the AGO2-RISC complex, explaining the direct cause of RBM7 knockdown-induced liver cancer cell senescence.

[0032] The invention discloses an application of an agent for downregulating RBM7 in the preparation of a drug for enhancing the killing of liver cancer cells by anti-aging cell drugs senolytics, wherein the agent for downregulating RBM7 expression comprises a vector for downregulating RBM7 expression and a small molecule inhibitor abemaciclib. The backbone vector of the vector for downregulating RBMS1 expression is a pLK0.1 vector; the primers for constructing the vector for downregulating RBM7 expression include an RBM7 shN1 primer pair and / or an RBM7 shN2 primer pair. Senolytic drugs include ABT-263 and AZD8035. The present invention uses ABT-263 / AZD8035 to treat the control group and RBM7 knockdown HCC cells respectively. The results of cytotoxicity experiments show that compared with the control group cells, RBM7 knockdown significantly sensitizes the killing effect of senolytic drugs ABT263 / AZD8035 on liver cancer cells. The present invention uses an FDA-approved drug library containing 3094 compounds for high-throughput screening and finds abemaciclib, a small molecule inhibitor of RBM7. After Huh7 cells were injected subcutaneously into nude mice to construct liver cancer cell xenografts, the drugs were administered by gavage, and the dosing regimens were drug solvent group; abemaciclib alone group; AZD8035 alone group; abemaciclib and AZD8035 combined group. Compared with the single-drug regimen, the combined treatment of abemaciclib and AZD8035 has a more significant effect in inhibiting tumor burden. The present invention proves that the combination of agents that downregulate RBM7 and anti-aging drugs senolytics can effectively kill liver cancer cells, providing a new theoretical basis and scheme for the application of the combination of pro-aging and anti-aging cell drugs in the treatment of liver cancer.

[0033] The use of a kit for diagnosing liver cancer and predicting the prognosis of liver cancer patients is prepared according to the expression level of RBM7, wherein the reagent preferably includes an antibody. The present invention does not specifically limit the source of the antibody, and a conventional commercially available antibody capable of detecting the expression level of RBM7 can be used. The analysis results of liver cancer samples in the CPTCA protein database showed that RBM7 was more highly expressed in liver cancer than in normal tissues. Protein immunoblotting experiments and real-time fluorescence quantitative PCR techniques have shown that RBM7 expression is higher in liver cancer tissues than in paracancerous tissues. Correlation analysis between RBM7 expression and survival of liver cancer patients showed that liver cancer patients with high RBM7 expression had a shorter overall survival, while liver cancer patients with low RBM7 expression had a longer overall survival. Reagents for detecting the expression level of RBM7 can be used to prepare a liver cancer diagnostic kit, which is helpful for achieving early detection of liver cancer and prediction of patient prognosis in clinical practice.

[0034] The embodiments of the present invention are further described in detail below in conjunction with the accompanying drawings and examples.

[0035] As attached Figure 1 To Attachment Fig. 9 As shown:

[0036] Example 1 Liver cancer patients with high RBM7 expression have a shorter survival period

[0037] The results of the analysis of liver cancer samples in the CPTCA protein database showed that RBM7 was more highly expressed in liver cancer than in normal tissues ( Figure 1 A). Western blotting experiments verified the expression of RBM7 in frozen fresh tissues of liver cancer and corresponding adjacent tumors. The results showed that the abundance of RBM7 protein was higher in tumor samples ( Figure 1 B). Real-time fluorescence quantitative PCR was used to analyze the RNA level of RBM7 in liver cancer and corresponding adjacent frozen fresh tissues. The results also showed that RBM7 expression was higher in liver cancer tissues ( Figure 1 C) Correlation analysis between RBM7 expression and survival of liver cancer patients showed that liver cancer patients with high RBM7 expression had a shorter overall survival, while liver cancer patients with low RBM7 expression had a longer overall survival ( Figure 1 D).

[0038] The specific technical solutions are as follows:

[0039] Real-time quantitative PCR (qRT-PCR)

[0040] Total RNA was extracted using Trizol extraction method, cDNA was synthesized using Evo-MLV Plus 1st StrandcDNA Synthesis Kit from Acry Biotech, and the expression of gene RNA level was detected using MonAmp TM chemoHS qPCR reagent.

[0041] qPCR reaction system

[0042]

[0043] qPCR reaction procedure

[0044]

[0045]

[0046] Example 2 Knockdown of RBM7 inhibits the proliferation of liver cancer cells

[0047] In order to explore the function of RBM7 in liver cancer, the pLKO.1-RBM7-sh1 and pLKO.1-RBM7-sh2 lentiviral systems were used to infect HepG2, SNU449 and Huh7 liver cancer cell lines. Western blotting experiments showed that compared with the control group (transfected with pLKO.1 plasmid empty vector), RBM7 expression was downregulated in cells transfected with shRNA, proving that the stable cell line with RBM7 knockdown was successfully constructed ( Figure 2 A). The clone formation experiment and growth curve experiment were performed using the constructed liver cancer stable cell line. The results showed that RBM7 knockdown significantly inhibited the growth of HepG2 ( Figure 2 B), SNU449( Figure 2 C) and Huh7 cells ( Figure 2 D) proliferation capacity.

[0048] In order to explore the in vivo effect of downregulating RBM7 on inhibiting liver cancer growth, the present invention conducted a nude mouse transplant tumor experiment. The specific operation was to inject 3×106 RBM7 knockdown Huh7 cells or control empty cells into the armpits of 4-6 week old BALB / c nude immunodeficient mice, measure the tumor size every two days until the 22nd day, dissect the mice and take pictures of the tumors. The results showed that knocking down RBM7 significantly inhibited the ability of liver cancer cells to form tumors in nude mice subcutaneously ( Figure 3 A). The weight statistics of nude mouse subcutaneous transplanted tumors show that knockdown of RBM7 inhibited the weight of nude mouse subcutaneous transplanted tumors ( Figure 3 B). The volume of the subcutaneous transplanted tumor in nude mice was obtained by measuring the longest diameter (L) and the maximum horizontal diameter (W) in the vertical direction of the subcutaneous tumor with a vernier caliper, and the tumor volume was calculated according to the formula: V = L × W2 / 2. The volume was measured every 2 days one week after the injection of cells. The results showed that RBM7 knockdown inhibited the growth and size of the subcutaneous transplanted tumor of liver cancer cells in nude mice ( Figure 3 C). In summary, compared with the control group (pLKO.1 plasmid empty transfected cells), the size and weight of subcutaneous tumors in nude mice with RBM7 knockdown were significantly inhibited, and the tumor growth rate was also slower.

[0049] The specific technical solutions are as follows:

[0050] 1 Plasmid construction

[0051] 1.1 Primer design and amplification

[0052] The design of RBM7 gene shRNA primers and p21 gene shRNA primers is shown in Table 1, and the empty plasmid was used as a control. Primer synthesis was completed by Genewise Biotechnology Co., Ltd.

[0053] Table 1 RBM7 gene shRNA primers and p21 gene shRNA primers

[0054]

[0055] Table 1 RBM7 gene shRNA primers and p21 gene shRNA primers

[0056] 1) Construction of pLK0.1-RBM7-sh1, pLK0.1-RBM7-sh2, pLK0.1-p21-sh1, pLK0.1-p21-sh2 vectors:

[0057] a) Oligonucleotide annealing: Add deionized water to dissolve the primers respectively, so that the final concentration of each primer is 10 μM. Prepare the reaction system in a 1.5 mL EP tube according to the reaction system shown in the table below. Pour 800 mL of water at 95°C into a beaker, place the EP tube into the beaker with a float, place a thermometer in the beaker to display the water temperature, place it on the laboratory bench, and slowly cool it to room temperature. The reaction system is shown in Table 2.

[0058] Table 2 Reaction system

[0059]

[0060] Note: The primers used for Forward oligo are RBM7 shN-F and p21 shN-F; the primers used for Reverse oligo are RBM7 shN-R and p21 shN-R;

[0061] b) Enzyme digestion of p1K0.1 vector / pLKO-Tet-ON vector (both purchased from Addgene): First, perform AgeI digestion, and the reaction system is as shown in Table 3.

[0062] Table 3 AgeI restriction enzyme digestion reaction system

[0063]

[0064]

[0065] Incubate in a water bath at 37°C for 1.5 hours

[0066] The above products were subjected to agarose gel electrophoresis and gel recovery, and then digested with EcoRI, the system is shown in Table 4.

[0067] Table 4 EcoR I restriction enzyme digestion reaction system

[0068]

[0069] Incubate in water bath at 37°C for 1.5 hours

[0070] Then, agarose gel electrophoresis is performed, the gel is cut, recovered and purified to obtain the final ligation product.

[0071] c) Connection, the system is shown in Table 5:

[0072] Table 5 Connection system

[0073]

[0074] Incubate in water bath at 16°C for 3 hours

[0075] The pLK0.1-RBM7-sh1, pLK0.1-RBM7-sh2 and pLK0.1-p21-sh1, pLK0.1-p21-sh2 vectors were constructed.

[0076] 1.3 Plasmid transformation and amplification

[0077] 1) Mixing and incubation: Add 5 μL of the ligation products of pLK0.1-RBM7-sh1, pLK0.1-RBM7-sh2, pLK0.1-p21-sh1, and pLK0.1-p21-sh2 obtained in 2.1.2 to 50 μL of Trans5a competent medium, flick to mix, and place on ice for 30 minutes.

[0078] 2) Heat shock: heat shock in a 42°C water bath for 45 seconds, then place on ice for 2 minutes.

[0079] 3) Cultivation: Add 500 μl of LB liquid culture medium without antibiotics and culture at 37°C in a shaking incubator for 1 h.

[0080] 4) Plate coating: Centrifuge briefly at room temperature, discard the supernatant and keep about 100 μL. Use a pipette to mix the precipitate and add it to the LB solid agar plate containing ampicillin. Use sterilized glass beads to mix the bacterial solution. After 20 minutes, invert and culture in a 37°C incubator overnight.

[0081] 5) Pick a single colony: The appearance of a colony after 12-16 hours indicates successful ligation and transformation. Pick the colony with a sterile pipette tip, add it to LB medium containing ampicillin, and shake it overnight at 37°C at 150 rpm.

[0082] 6) Plasmid extraction: The constructed pLK0.1-RBM7-sh1, pLK0.1-RBM7-sh2, pLK0.1-p21-sh1, and pLK0.1-p21-sh2 plasmids were extracted and purified using QIAGEN Plasmid MiniKits. Then Suzhou Genewise Biotechnology Co., Ltd. was commissioned to perform sequencing, and the sequencing results showed that the sequencing sequence was correct and the vector was successfully constructed.

[0083] 2 Construction of stable cell lines

[0084] 1) Lentiviral vector system packaging virus

[0085] Inoculate cells in a 10cm cell culture dish 24h in advance, and wait until the density of HEK293T cells reaches 90% the next day for transfection. During transfection, take 7.5μg psAX2, 2.5μg pMD2 auxiliary packaging plasmid and 10μg target gene plasmid and add them to 1.5mL Opti-MEM, gently shake and mix, and then add 30μL p3000 to mix. Prepare another tube and add 1.5mL Opti-MEM, take 20μL Lipofectamine 3000 transfection reagent and shake and mix. Then combine the two and mix them together. After incubation at room temperature for 10-15min, slowly add the liposome mixture to the HEK293T cells along the edge of the cell culture dish and place it in a 37℃ incubator for culture. After 12h, replace with fresh culture medium and continue to culture for 48h-72h. Collect the cell supernatant containing virus particles in a 15 mL centrifuge tube, centrifuge at 1500 rpm for 5 min, let the cells and cell debris sink to the bottom of the centrifuge tube, and then filter the supernatant using a 0.45 μm filter. The supernatant containing virus particles is divided into 1.5 mL centrifuge tubes and stored at -80°C.

[0086] 2) Virus infection and screening of stable cell lines

[0087] Virus infection is performed when the cell density reaches about 80%. Add the virus solution and fresh culture medium to the cells at a volume ratio of 1:1, and add 8μg / mL of polybrene infection-promoting reagent, gently shake and place in a 37-degree incubator for infection for 24 hours. After 24 hours, the cells are transferred and the complete culture medium is replaced. After the cells adhere to the wall, 5μg / mL of puromycin is added for screening (different cell lines have different sensitivities to puromycin, and it is necessary to find a suitable drug screening concentration). Continue to culture with drug addition for about a week, and replace with a low concentration of puromycin for maintenance.

[0088] Example 3 Knockdown of RBM7 induces senescence of liver cancer cells

[0089] The present invention observed through phase contrast microscopy that after endogenous RBM7 was knocked out, liver cancer cells changed into a flat shape, indicating that it may cause cell senescence. One of the characteristics of cell senescence is cell G1 / S cycle arrest. Flow cytometry results show that RBM7 knockdown promotes an increase in the proportion of liver cancer cells in the G1 / S phase ( Figure 4 A). Because the activity of β-galactosidase can indicate cell senescence, the SNU449 and HepG2 cells with stable knockdown of RBM7 and the corresponding control group were stained with β-galactosidase. The results showed that knockdown of RBM7 can significantly increase the proportion of positively stained cells ( Figure 4 B). Senescent cells can secrete different inflammatory factors. These senescence-related secreted factors can not only aggravate the senescence of their own cells, but also cause the senescence of neighboring cells in an autocrine or paracrine manner. The results of real-time fluorescence quantitative PCR technology showed that RBM7 knockdown significantly upregulated the expression of multiple inflammatory factors RNA levels in different liver cancer cell lines, including AREG, BMP2, CTSB, EBI3, TNF and TNFSF15 ( Figure 4 C). In the co-culture experiment, RBM7 knockdown senescent cells were co-cultured with normal cells with GFP green fluorescence for 4 days. The morphological changes of GFP cells were observed under a fluorescence microscope. The results showed that after co-culture, GFP cells underwent senescence-like changes, that is, the cells became flat, loose, and enlarged ( Figure 4 D). Immunoblotting experiments showed that knocking down RBM7 significantly inhibited the phosphorylation level of Rb and upregulated the expression of G1 / S phase arrest protein P21 ( Figure 4 E). In conclusion, knockdown of RBM7 by shRNA can induce senescence in liver cancer cells.

[0090] The specific technical solutions are as follows:

[0091] Cell senescence β-galactosidase staining (SA-β-Ga l staining)

[0092] Cells with different treatments were seeded in 6-well plates 48 hours in advance, the cell culture medium was discarded, washed once with PBS, and 1 mL of β-galactosidase staining fixative was added to fix at room temperature for 20 minutes, and the fixative was discarded and washed 3 times with PBS, each time for 3 minutes. 1 mL of staining solution was added to each well and stained in a constant temperature incubator without carbon dioxide at 37°C for 48-72 hours. To prevent evaporation, the 6-well plate was sealed with sealing film on all sides. The staining was observed under an optical microscope. If the cells cannot be counted in time, 2 mL of PBS was added after the staining solution was discarded and stored at 4 degrees for several days. Alternatively, the sealing agent can be used to seal the plates at 4 degrees for long-term storage. If crystallization occurs during the staining process, 70% alcohol or dimethyl sulfoxide (DMSO) was added for washing after the staining was completed. Cells in 4 different fields of view were counted in each group. The experiment was repeated three times independently.

[0093] Example 4 Knockdown of RBM7 promotes cell senescence by regulating p21 mRNA stability

[0094] According to existing reports, p21 is an important senescence activator. To explore whether RBM7 knockdown-induced cell senescence is through upregulation of p21, the present invention uses two shRNA lentiviral systems with different sequences to knock down p21. Immunoblotting experiments show that p21 expression is successfully downregulated in RBM7 stable knockdown cell lines, proving that p21 knockdown is successful ( Figure 5 A). In the phenotypic reversion experiment, β-galactosidase staining results showed that the two shRNAs of p21 reversed the cell senescence phenotype caused by knocking down RBM7, and consistent results were obtained in two different liver cancer cell lines, HepG2 and SNU449 ( Figure 5 B). CCK8 experiments showed that knockdown of RBM7 significantly inhibited the growth of liver cancer cells, while knockdown of p21 significantly restored the proliferation rate of cells ( Figure 5 C). The clone formation experiment showed that knockdown of RBM7 significantly inhibited the clone formation ability of liver cancer cells, while knockdown of p21 had a significant recovery effect ( Figure 5 D). The above results indicate that downregulation of RBM7 induced cell senescence by upregulating p21.

[0095] Real-time fluorescence quantitative PCR technology was used to explore the mechanism and found that RBM7 knockdown significantly increased the mRNA half-life of p21 transcript (CDKN1A) ( Figure 6 A). To verify the regulation of RBM7 on CDKN1A stability, a luciferase reporter gene containing the CDKN1A 3'-UTR sequence was constructed and transfected into liver cancer cells via liposomes. The results of microplate reader assay showed that knocking down RBM7 significantly increased luciferase activity ( Figure 6 B). Different truncations of CDKN1A 3-UTR were applied to biotin-labeled RNA-pull down experiments, and the results showed that the region containing 500-1050 nt has the ability to enrich RBM7 ( Figure 6 C). Based on this, a potential binding site for RBM7 (UUUUN) was found on the 500-1050 nt sequence of CDKN1A 3-UTR. RNA immunoprecipitation (RIP) experiments showed that RBM7 bound to the region with potential RBM7 binding site in CDKN1A 3-UTR ( Figure 6 D). According to TargetScan combined with RNA secondary structure prediction analysis, the binding site of miR-93-5p is located near the potential binding region of RBM7 in CDKN1A 3-UTR ( Figure 6E). The biotin-avidin system showed that the 500-1050nt region of CDKN1A 3-UTR can also interact with AGO2 ( Figure 6 F). Further RIP analysis showed that upregulation of RBM7 significantly enhanced the interaction between AGO2 and the 3-UTR region of CDKN1A ( Figure 6 G). In summary, RBM7 regulates p21 mRNA stability by recruiting the AGO2-RISC complex, explaining the direct reason why RBM7 knockdown induces liver cancer cell senescence.

[0096] The specific technical solutions are as follows:

[0097] Dual luciferase assay

[0098] 1) Transfect cells. 5x105 RBM7 knockdown or control cells were seeded in a 24-well plate 24 hours in advance. The next day, the reporter gene and Renilla plasmid were co-transfected with the transfection reagent Lipofectamine 3000 (100 ng of reporter gene and 50 ng of Renilla plasmid). The cells were lysed 48 hours after transfection.

[0099] 2) Determination of luciferase activity. Wash the cells once with PBS, add 100 μL lysis solution and lyse at room temperature for 15 minutes. Melt the prepared LAR II (LAR II is the substrate of Firefly Luciferase) and Stop solution (substrate of Renilla Luciferase, which terminates the reaction of LAR II) at room temperature in advance. Use an opaque 96-well plate, add 10 μL of cell lysis solution, add 50 μL of LAR II solution with a spray gun, and read the fluorescence value using a multifunctional microplate reader, which is the value of Firefly luciferase. Then add 50 μL of Stop solution, and the microplate reader reads the value of Renilla luciferase. When processing the data, calculate the fluorescence ratio of Firefly / Renilla, use the control group as the standard, and compare the experimental group with it, so as to detect the level of luciferase activity in the experimental group.

[0100] Example 5 Knockdown of RBM7 sensitizes the killing effect of senolytic drugs on liver cancer cells.

[0101] Cellular senescence blocks the cell cycle and thus curbs tumor growth, however, if cell senescence persists, it may have a harmful effect on the tissue environment. In clinical trials, the combination of senolytics that selectively target and eliminate senescent cells and induced senescence therapy has achieved good results. Navitoclax, or ABT-263, is an inhibitor of an anti-apoptotic BCL-2 family member (often upregulated in senescent cells), which has shown good efficacy in a variety of solid tumors in combination with methods that promote senescence. Therefore, the present invention used ABT-263 to treat the control group and RBM7 knockdown HCC cells, respectively. The results of the cytotoxicity experiment showed that compared with the control group cells, RBM7 knockdown significantly sensitized the killing effect of ABT263 on liver cancer cells ( Figure 7 A). AZD8055 is an mTOR inhibitor that has been shown to have anti-aging properties. Cytotoxicity experiments have shown that compared with the group treated with AZD8055 alone, knocking down RBM7 combined with AZD8055 significantly enhanced the killing effect on liver cancer cells ( Figure 7 B). This indicates that RBM7 knockdown and the anti-aging agents ABT-263 or AZD8055 have a combined killing effect on liver cancer cells.

[0102] In order to explore the potential clinical application of targeting RBM7 to treat liver cancer, the present invention uses a drug library containing 3094 compounds approved by the FDA for high-throughput screening to identify small molecule inhibitors of RBM7. The specific method is to construct a monoclonal liver cancer cell line stably transfected with GFP-RBM7 fusion protein, and identify four compounds that inhibit the signal intensity of GFP-RBM7 by combining the proliferation inhibition rate and the senescence indicator β-galactosidase activity ( Figure 8 A). Among them, abemaciclib is known as a CDK4 / 6 inhibitor, but its therapeutic effect in liver cancer is still unclear. According to the half-inhibitory concentration IC50 value of abemaciclib in each liver cancer cell line, liver cancer cells were treated with different concentrations of drugs for 24-48 hours. The results of immunoblotting experiments showed that abemaciclib could significantly downregulate RBM7 protein levels, enhance p21 expression, and reduce RB phosphorylation ( Figure 8 B). Plate cloning experiments have shown that abemaciclib treatment can lead to a dose-dependent decrease in the cloning ability of liver cancer cells ( Figure 8 C). SA-β-gal staining experiments showed that abemaciclib treatment significantly increased the proportion of senescent cells ( Figure 8 D). The above results prove that the drug abemaciclib can downregulate RBM7 expression and promote the senescence of liver cancer cells.

[0103] In order to explore whether abemaciclib can play a functional role in the "combination" aging-targeted treatment of HCC, the present invention evaluated the effect of abemaciclib combined with AZD8035 on the viability of liver cancer cells. The results of cytotoxicity experiments showed that compared with monotherapy, abemaciclib combined with AZD8035 treatment can significantly kill liver cancer cells ( Fig. 9 A) and inhibit cell proliferation ( Fig. 9 B). In the animal treatment model, the present invention first subcutaneously injected Huh7 cells into nude mice to construct xenograft tumors, and verified the synergistic anticancer effect of the two drugs in vivo by oral gavage. Compared with the single-drug regimen, the combination of abemaciclib and AZD8035 can strongly inhibit tumor burden and reduce the development of HCC tumors ( Fig. 9 C). Immunohistochemistry was used to analyze the transplanted tumor samples. The results showed that the mice treated with abemaciclib / AZD8035 combination had more obvious apoptosis and a significant decrease in Ki-67 positive cells. The abemaciclib alone treatment group showed inhibition of RBM7 expression and increase in SA-β-gal levels. The AZD8035 alone treatment group showed blockade of the mTOR pathway (( Fig. 9 D) In ​​summary, the RBM7 inhibitor abemaciclib combined with the anti-aging drug senolytics can effectively inhibit the progression of liver cancer in the transplanted tumor model

[0104] Application: Pro-cell senescence-related therapies combined with anti-aging drugs to eliminate tumor cells have become a research hotspot, but there is still a lack of clinical drugs that effectively induce tumor cell senescence. Studies in recent years have shown that RNA-binding proteins are involved in important cellular activities, and their abnormal expression is closely related to various aspects of tumor malignant characteristics. Therefore, systematic identification of the function of RNA-binding proteins in liver cancer progression and liver cancer cell senescence is helpful for the development of effective anti-tumor targeted drugs. In addition, by using a high-throughput shRNA library combined with high-content small molecule compound screening, the present invention reveals the new function and mechanism of RBM7 in liver cancer cell senescence by regulating the stability of p21 mRNA, and also provides new ideas and solutions for liver cancer treatment by targeting RBM7 combined with anti-aging drugs senolytics, opening up new clinical application prospects for aging-related tumor treatment strategies, and at the same time indicating that RBM7 expression levels and gene status may be used as biomarkers for designing anti-liver cancer treatment plans for pro-aging therapies.

[0105] The embodiments of the present invention are provided for the purpose of illustration and description. Although the embodiments of the present invention have been shown and described above, it can be understood that the above embodiments are exemplary and cannot be understood as limitations of the present invention. Ordinary technicians in this field can change, modify, replace and modify the above embodiments within the scope of the present invention.

Claims

1. Use of an agent for downregulating RBM7 expression in the preparation of a drug for treating liver cancer, characterized in that: The reagent for downregulating RBM7 expression includes a RBM7 knockdown vector and a small molecule compound abemaciclib; The backbone vector of the RBM7 knockdown vector is a pLK0.1 vector; the primers for constructing the RBM7 knockdown vector include an RBM7 sh1 primer pair and an RBM7 sh2 primer pair; The RBM7 sh1 primer pair includes RBM7 sh1-F with a nucleotide sequence as shown in SEQ ID NO.1 and RBM7 sh1-R with a nucleotide sequence as shown in SEQ ID NO.2; the RBM7 sh2 primer pair includes RBM7 sh2-F with a nucleotide sequence as shown in SEQ ID NO.3 and RBM7 sh2-R with a nucleotide sequence as shown in SEQ ID NO.

4.

2. Use of an agent for downregulating RBM7 in the preparation of a drug for inhibiting the proliferation of liver cancer cells, characterized in that: The reagent for downregulating RBM7 includes a vector for knocking down RBM7 and a small molecule compound abemaciclib; The backbone vector of the RBM7 knockdown vector is a pLK0.1 vector; the primers for constructing the RBM7 knockdown vector include an RBM7 sh1 primer pair and an RBM7 sh2 primer pair; The RBM7 sh1 primer pair includes RBM7 sh1-F with a nucleotide sequence as shown in SEQ ID NO.1 and RBM7 sh1-R with a nucleotide sequence as shown in SEQ ID NO.2; the RBM7 sh2 primer pair includes RBM7 sh2-F with a nucleotide sequence as shown in SEQ ID NO.3 and RBM7 sh2-R with a nucleotide sequence as shown in SEQ ID NO.

4.

3. Use of an agent for downregulating RBM7 in the preparation of a drug for enhancing the killing of liver cancer cells by anti-aging cell drugs senolytics, characterized in that: The reagent for downregulating RBM7 includes a vector for knocking down RBM7 and a small molecule compound abemaciclib; The backbone vector of the RBM7 knockdown vector is a pLK0.1 vector; the primers for constructing the RBM7 knockdown vector include an RBM7 sh1 primer pair and an RBM7 sh2 primer pair; The RBM7 sh1 primer pair includes RBM7 sh1-F with a nucleotide sequence as shown in SEQ ID NO.1 and RBM7 sh1-R with a nucleotide sequence as shown in SEQ ID NO.2; the RBM7 sh2 primer pair includes RBM7 sh2-F with a nucleotide sequence as shown in SEQ ID NO.3 and RBM7 sh2-R with a nucleotide sequence as shown in SEQ ID NO.4; The anti-aging cell drug is ABT-263 or AZD8055.